Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- EPKINLY PLUS RITUXIMAB AND LENALIDOMIDE (EPKINLY + R2) IS NOW THE FIRST AND ONLY BISPECIFIC ANTIBODY COMBINATION THERAPY AVAILABLE FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY - IN THE PHASE 3 EPCORE FL-1 TRIAL, EPKINLY + R2 DEMONSTRATED SIGNIFICANTLY SUPERIOR PROGRESSION-FREE SURVIVAL AND OVERALL RESPONSE RATES COMPARED TO STANDARD OF CARE R2 WITH APPROXIMATELY 3 OUT OF 4 PATIENTS ACHIEVING A COMPLETE RESPONSE - APPROVAL MARKS THIRD INDICATION FOR EPKINLY AND FIRST-EVER FDA APPROVAL FOR A BISPECIFIC COMBINATION THERAPY IN LYMPHOMA NORTH CHICAGO, ILL. , NOV. 18, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT EPKINLY (EPCORITAMAB-BYSP), A T-CELL ENGAGING BISPECIFIC ANTIBODY ADMINISTERED SUBCUTANEOUSLY, IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (EPKINLY + R2) IS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL).

ABBVIE ANNOUNCES U.S. FDA APPROVAL OF EPKINLY (EPCORITAMAB-BYSP) IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

AS A LEADER IN MIGRAINE TREATMENT, ABBVIE IS COMMITTED TO ADDRESSING THE IMPACT OF MIGRAINE IN THE WORKPLACE. 2025 HONOREES REPRESENT A DIVERSE GROUP OF ACHIEVERSFROM TEACHERS AND AUTHORS TO SMALL BUSINESS OWNERS AND ASPIRING YOGA AND MEDITATION INSTRUCTORSEACH REDEFINING SUCCESS WHILE LIVING WITH MIGRAINE.

ABBVIE ANNOUNCES 20 RECIPIENTS OF MIGRAINE CAREER CATALYST AWARD

-A TOTAL OF 17 ABSTRACTS, INCLUDING THREE ACCEPTED FOR PRESENTATION IN THE COSMETIC "TOP TEN" SESSION, UNDERSCORE ALLERGAN AESTHETICS' GLOBAL INDUSTRY LEADERSHIP ACROSS MULTIPLE AESTHETIC CATEGORIES -ORAL ABSTRACT PRESENTATIONS INCLUDE PHASE 3 CLINICAL STUDY RESULTS FOR FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E(TRENIBOTULINUMTOXINE) AND RESULTS FROM A PHASE 4 STUDY EVALUATING NATURAL OUTCOMES AND PATIENT SATISFACTION IN A DIVERSE POPULATION FOLLOWING USE OF 64 UNITS OF BOTOXCOSMETIC (ONABOTULINUMTOXINA) FOR TREATMENT OF UPPER FACIAL LINES - EXPERT PANEL DISCUSSION EXPLORES NEW HYALURONIC ACID INJECTABLE FILLERS REPORT, ALONG WITH CURRENT USE, FACTS, AND REAL-WORLD SATISFACTION DATA IRVINE, CALIF. , NOV. 12, 2025 /PRNEWSWIRE/ --ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED IT WILL PRESENT DATA HIGHLIGHTING EFFICACY, SAFETY AND PATIENT-REPORTED OUTCOMES ACROSS ITS PORTFOLIO DURING THE 2025 AMERICAN SOCIETY OF DERMATOLOGIC SURGERY (ASDS) ANNUAL MEETING, NOVEMBER 13-16, 2025, IN CHICAGO, ILLINOIS.

ALLERGAN AESTHETICS UNVEILS NEW DATA AT 2025 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ANNUAL MEETING SHOWCASING TRANSFORMATIVE INNOVATION AND PORTFOLIO EXCELLENCE

PARMA, ITALY, NOV. 12, 2025 (GLOBE NEWSWIRE) -- CHIESI GROUP TODAY ANNOUNCED IT HAS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ALIADA THERAPEUTICS, A WHOLLY OWNED SUBSIDIARY OF ABBVIE, TO ADVANCE BLOOD-BRAIN BARRIER (BBB)-CROSSING PLATFORM TECHNOLOGY IN LYSOSOMAL STORAGE DISORDERS (LSD) TO ADDRESS CHALLENGING DISEASE AREAS WITH HIGH UNMET NEED.

CHIESI GROUP ENTERS INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ALIADA THERAPEUTICS, A WHOLLY OWNED SUBSIDIARY OF ABBVIE, TO ADVANCE BLOOD-BRAIN BARRIER-CROSSING PLATFORM TECHNOLOGY IN LYSOSOMAL STORAGE DISORDERS

REPORTS THIRD-QUARTER DILUTED EPS OF $0.10 ON A GAAP BASIS, A DECREASE OF 88.6 PERCENT; ADJUSTED DILUTED EPS OF $1.86, A DECREASE OF 38.0 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $1.50 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE  DELIVERS THIRD-QUARTER NET REVENUES OF $15.776 BILLION, AN INCREASE OF 9.1 PERCENT ON A REPORTED BASIS OR 8.4 PERCENT ON AN OPERATIONAL BASIS  THIRD -QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $7.885 BILLION, AN INCREASE OF 11.9 PERCENT ON A REPORTED BASIS, OR 11.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $4.708 BILLION; GLOBAL RINVOQ NET REVENUES WERE $2.184 BILLION; GLOBAL HUMIRA NET REVENUES WERE $993 MILLION  THIRD -QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $2.841 BILLION, AN INCREASE OF 20.2 PERCENT ON A REPORTED BASIS, OR 19.6 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $934 MILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $985 MILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $642 MILLION  THIRD -QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.682 BILLION, A DECREASE OF 0.3 PERCENT ON A REPORTED BASIS, OR 1.3 PERCENT ON AN OPERATIONAL BASIS; GLOBAL IMBRUVICA NET REVENUES WERE $706 MILLION; GLOBAL VENCLEXTA NET REVENUES WERE $726 MILLION; GLOBAL ELAHERE NET REVENUES WERE $170 MILLION  THIRD -QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.193 BILLION, A DECREASE OF 3.7 PERCENT ON A REPORTED BASIS, OR 4.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $637 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $253 MILLION  RAISES 2025 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $10.38 - $10.58 TO $10.61 - $10.65, WHICH INCLUDES AN UNFAVORABLE IMPACT OF $2.05 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE INCURRED YEAR-TO-DATE THROUGH THE THIRD QUARTER 2025  ANNOUNCES 2026 DIVIDEND INCREASE OF 5.5 PERCENT, BEGINNING WITH DIVIDEND PAYABLE IN FEBRU

ABBVIE REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS

ALLERGAN AESTHETICS GIVES PATIENTS EXCITING BOTOX COSMETIC OFFERS ONLY IN THE ALL APP BUY ONE $50 GIFT CARD, GET ONE FREE, PLUS, REGISTER, BOOK A CONSULTATION, AND GET TREATED FOR A CHANCE TO WIN $25,000*  IRVINE, CALIF. , OCT. 29, 2025 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE SEVENTH ANNUAL BOTOX COSMETIC DAYWILL TAKE PLACE ON WEDNESDAY, NOVEMBER 19, 2025.

THE ONE & ONLY BOTOX COSMETIC (ONABOTULINUMTOXINA) DAY RETURNS NOVEMBER 19 WITH THE BIGGEST CELEBRATION OF THE YEAR

IN TWO REPLICATE PHASE 3 STUDIES, UPADACITINIB (RINVOQ  ) ACHIEVED THE CO-PRIMARY ENDPOINTS OF 50% REDUCTION IN TOTAL VITILIGO AREA SCORING INDEX (T-VASI 50) FROM BASELINE AND 75% REDUCTION IN FACIAL VITILIGO AREA SCORING INDEX (F-VASI 75) FROM BASELINE AT WEEK 481 BOTH STUDIES MET KEY RANKED SECONDARY ENDPOINTS1 NORTH CHICAGO, ILL. , OCT. 29, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCEDPOSITIVE TOPLINE RESULTS FROM TWO REPLICATE PHASE 3 STUDIES EVALUATING THE SAFETY AND EFFICACY OF UPADACITINIB (RINVOQ;15 MG, ONCE DAILY IN ADULT AND ADOLESCENT PATIENTS LIVING WITH NON-SEGMENTAL VITILIGO (NSV).1 NSV, THE MOST COMMON FORM OF VITILIGO (OCCURRING IN OVER 90% OF PATIENTS), IS CHARACTERIZED BY SYMMETRICAL AND BILATERAL WHITE PATCHES ON BOTH SIDES OF THE BODY.2-4 "VITILIGO IS MORE THAN A SKIN CONDITION  IT'S A CHRONIC AUTOIMMUNE DISEASE THAT CAN DEEPLY AFFECT A PERSON'S CONFIDENCE, IDENTITY AND DAILY LIFE,"SAID KORI WALLACE, M.D.

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 PIVOTAL STUDIES EVALUATING UPADACITINIB (RINVOQ) IN ADULTS AND ADOLESCENTS WITH VITILIGO

EACH WINNER WILL BE AWARDED A $20,000 GRANT TO FUEL THEIR BUSINESSES. SINCE THE PROGRAM'S INCEPTION, BOTOX COSMETIC HAS AWARDED MORE THAN $1 MILLION IN GRANTS TO THE CONFIDENCE PROJECT ENTREPRENEURS.

THE CONFIDENCE PROJECT BY BOTOX COSMETIC (ONABOTULINUMTOXINA) UNVEILS THIS YEAR'S GRANT RECIPIENTS

UPADACITINIB DEMONSTRATED SUPERIORITY VERSUS ADALIMUMAB FOR PRIMARY ENDPOINT OF ACHIEVING LOW DISEASE ACTIVITY (DAS28-CRP3.2) AND RANKED SECONDARY ENDPOINT OF REMISSION(DAS28-CRP

RINVOQ (UPADACITINIB) DEMONSTRATED SUPERIORITY VERSUS HUMIRA (ADALIMUMAB) FOR PRIMARY ENDPOINT IN A HEAD-TO-HEAD STUDY IN RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED FIRST TNF INHIBITOR

ACQUISITION EXPANDSABBVIE'S PSYCHIATRY PIPELINE WITH THE ADDITION OF A NEXT-GENERATION PSYCHEDELIC COMPOUND CURRENTLY IN PHASE 2 DEVELOPMENT FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD). NORTH CHICAGO, ILL.

ABBVIE COMPLETES ACQUISITION OF GILGAMESH PHARMACEUTICALS' BRETISILOCIN

CAMBRIDGE, MASS.--(BUSINESS WIRE)--ENVERIC BIOSCIENCES (NASDAQ: ENVB) (ENVERIC OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING NEXT-GENERATION NEUROPLASTOGENIC SMALL MOLECULES TO ADDRESS PSYCHIATRIC AND NEUROLOGICAL DISORDERS, TODAY ANNOUNCED THAT IT HAS HIRED INTELLECTUAL PROPERTY POWERHOUSE FISH AND RICHARDSON P.C. TO CONTEST A POST-GRANT REVIEW (PGR) PETITION FILED BY GILGAMESH PHARMACEUTICALS (GILGAMESH) AGAINST ENVERIC'S ISSUED U.S. PATENT NO. 12,138,276 (THE'276 PATENT,) ENTITLED,.

ENVERIC BIOSCIENCES HIRES IP POWERHOUSE TO DEFEND ITS U.S. PATENT WITH CLAIMS RELEVANT TO BRETISILOCIN, RECENTLY ACQUIRED BY ABBVIE IN $1.2 BILLION DEAL

-    UPDATED INDICATION ALLOWS THE USE OF RINVOQ (UPADACITINIB) PRIOR TO THE USE OF TUMOR NECROSIS FACTOR (TNF) BLOCKING AGENTS IN PATIENTS FOR WHOM USE OF THESE TREATMENTS IS CLINICALLY INADVISABLE AND WHO HAVE RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY NORTH CHICAGO, ILL. , OCT. 13, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) THAT UPDATES THE INDICATION STATEMENT FOR RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD).

U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES UPDATED INDICATION STATEMENT FOR RINVOQ (UPADACITINIB) FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

NEW DATA FROMTELISOTUZUMAB ADIZUTECAN (TEMAB-A) AND ABBV-706 ACROSS PANCREATIC, COLORECTAL, AND SOLID TUMORS, HIGHLIGHT PROGRESS IN ABBVIE'S GROWING ADC PORTFOLIO DESIGNED TO TARGET DIFFICULT-TO-TREAT CANCERS. NORTH CHICAGO, ILL.

ABBVIE TO PRESENT NEW DATA AT ESMO 2025 REINFORCING LEADERSHIP IN ADVANCING TARGETED THERAPIES FOR SOLID TUMORS

BY THE MAKERS OF BOTOX COSMETIC (ONABOTULINUMTOXINA), SKINMEDICA'S NEW PACKAGING FEATURES A REFRESHED LOGO, MODERNIZED LOOK, AND LUXE COPPER COLOR PALETTE. THE BRAND'S NEW HA5 MOISTURIZER IS DESIGNED TO SUPPORT THE SKIN BARRIER AND MICROBIOME FOR BOUNCY, DEWY, AND SOFT SKIN.

SKINMEDICA DEBUTS REIMAGINED PACKAGING AND UNVEILS NEW HA5 HYDRA COLLAGEN WATER BURST MOISTURIZER

ONABOTULINUMTOXINA (BOTOX) MET THE PRIMARY ENDPOINT IN THE PHASE 2 TRIAL, DEMONSTRATING A STATISTICALLY SIGNIFICANT IMPROVEMENT FROM BASELINE IN THE TREMOR DISABILITY SCALE-REVISED (TREDS-R) TOTAL UNILATERAL SCORE COMPARED TO PLACEBO.1 THE TRIAL ALSO MET ALL SIX SECONDARY ENDPOINTS.2 RESULTS FROM SAFETY ANALYSES WERE GENERALLY CONSISTENT WITH THE WELL-ESTABLISHED SAFETY PROFILE OF ONABOTULINUMTOXINA.1 NORTH CHICAGO, ILL. , OCT. 6, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 2 ELATE TRIAL EVALUATING THE SAFETY AND EFFICACY OF ONABOTULINUMTOXINA (BOTOX) COMPARED TO PLACEBO FOR THE TREATMENT OF UPPER LIMB ESSENTIAL TREMOR.

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 ELATE TRIAL EVALUATING ONABOTULINUMTOXINA (BOTOX) FOR THE TREATMENT OF UPPER LIMB ESSENTIAL TREMOR

NORTH CHICAGO, ILL. , OCT. 2, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL ANNOUNCE ITS THIRD-QUARTER 2025 FINANCIAL RESULTS ON FRIDAY, OCTOBER 31, 2025, BEFORE THE MARKET OPENS.

ABBVIE TO HOST THIRD-QUARTER 2025 EARNINGS CONFERENCE CALL

THIS AGREEMENT GRANTS VIZIENT CLIENTS ENHANCED ACCESS TO NATRELLE, THE BROADEST SELECTION OF BREAST IMPLANT OPTIONS ON THE MARKET. IRVINE, CALIF.

NATRELLE AWARDED SUPPLIER AGREEMENT FROM VIZIENT

EXPANSION INCREASES BIOLOGICS MANUFACTURING FOR IMMUNOLOGY AND ONCOLOGY MEDICINES MILESTONE MARKS PROGRESS ON ABBVIE'S LONG-TERM COMMITMENT TO U.S. MANUFACTURING FURTHERS LONGSTANDING COMMITMENT TO ABBVIE'S MASSACHUSETTS SITES AND WORKFORCE NORTH CHICAGO, ILL. , SEPT. 30, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE START OF CONSTRUCTION OF A $70 MILLION EXPANSION AT ITS ABBVIE BIORESEARCH CENTER (ABC) IN WORCESTER, MASS.

ABBVIE BEGINS CONSTRUCTION ON $70 MILLION EXPANSION TO FURTHER INCREASE BIOLOGICS MANUFACTURING AND R&D PRESENCE IN THE U.S.

TOKYO, JAPAN AND CAMBRIDGE AND LONDON, UK, 30 SEPTEMBER 2025  NXERA PHARMA CO., LTD. (NXERA OR THE COMPANY; TSE 4565) ANNOUNCES THAT IT HAS REACHED A SECOND IMPORTANT R&D MILESTONE UNDER ITS MULTI-TARGET DISCOVERY COLLABORATION WITH ABBVIE FOCUSED ON NEUROLOGICAL DISEASES, RESULTING IN A PAYMENT OF US$10 MILLION TO NXERA.

NXERA PHARMA TO RECEIVE US$10 MILLION MILESTONE PAYMENT FROM ABBVIE UNDER COLLABORATION TARGETING NEUROLOGICAL DISEASES

NEW STATE-OF-THE-ART ACTIVE PHARMACEUTICAL INGREDIENT (API) FACILITY WILL MANUFACTURE IMMUNOLOGY, ONCOLOGY AND NEUROSCIENCE MEDICINES FACILITY EXPECTED TO BE FULLY OPERATIONAL AND SERVING PATIENTS BY 2027 MILESTONE MARKS PROGRESS ON ABBVIE'S LONG-TERM COMMITMENT TO U.S. MANUFACTURING NORTH CHICAGO, ILL. , SEPT. 29, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE START OF CONSTRUCTION OF ITS NEW ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING PLANT IN NORTH CHICAGO, ILLINOIS.

ABBVIE BREAKS GROUND ON NEW NORTH CHICAGO ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING FACILITY

THE LIST PRICE WILL BE CONSISTENT WITH THE UNITED STATES TO REFLECT THE VALUE OF THE INNOVATION ABBVIE IS COMMITTED TO ENSURING THAT DEVELOPED NATIONS FULLY RECOGNIZE THE VALUE OF OUR MEDICINES IN IMPROVING PATIENT OUTCOMES, CONSISTENT WITH THE LEVEL OF RECOGNITION IN THE UNITED STATES NORTH CHICAGO, ILL. , SEPT. 29, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED PLANS TO LAUNCH ELAHERE(MIRVETUXIMAB SORAVTANSINE-GYNX) IN THE U.K. AT A LIST PRICE EQUAL TO THE U.S., REFLECTING THE ADVANCED INNOVATION AND VALUE OF THE TREATMENT FOR ADULT PATIENTS WITH FOLATE RECEPTOR-ALPHA (FR) POSITIVE, PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO HAVE RECEIVED ONE TO THREE PRIOR SYSTEMIC TREATMENT REGIMENS.1 ELAHERE IS THE FIRST-AND-ONLY APPROVED FR-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) MEDICINE.

ABBVIE ANNOUNCES UK PRICING STRATEGY FOR ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX)

SUBMISSION SUPPORTED BY DATA FROM THE PHASE 3 TEMPO PROGRAM THAT DEMONSTRATED SYMPTOMATIC IMPROVEMENT ACROSS THE PARKINSON'S DISEASE SPECTRUM POSITIVE RESULTS ACROSS ALL THREE PHASE 3 TEMPO TRIALS REINFORCE THE POTENTIAL OF TAVAPADON, A NOVEL SELECTIVE DOPAMINE D1/D5 RECEPTOR PARTIALAGONIST, IN PARKINSON'S DISEASE IF APPROVED, TAVAPADON WILL ENHANCE ABBVIE'S LEADERSHIP IN PARKINSON'S DISEASE BY PROVIDING PATIENTS WITH A ONCE DAILY ORAL TREATMENT OPTION NORTH CHICAGO, ILL. , SEPT. 26, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT HAS SUBMITTED A NEW DRUG APPLICATION (NDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TAVAPADON, A NOVEL SELECTIVE DOPAMINE D1/D5 RECEPTOR PARTIALAGONIST THAT WAS STUDIED AS A ONCE DAILY ORAL TREATMENT FOR PARKINSON'S DISEASE.

ABBVIE SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR TAVAPADON FOR THE TREATMENT OF PARKINSON'S DISEASE

SPHERIX GLOBAL INSIGHTS FINDS MAJORITY OF SPECIALISTS EXPECT RINVOQ'S UPTAKE TO ACCELERATE, WITH POTENTIAL IMPLICATIONS BRANCHING TO THE POLYMYALGIA RHEUMATICA LANDSCAPE. SPHERIX GLOBAL INSIGHTS FINDS MAJORITY OF SPECIALISTS EXPECT RINVOQ'S UPTAKE TO ACCELERATE, WITH POTENTIAL IMPLICATIONS BRANCHING TO THE POLYMYALGIA RHEUMATICA LANDSCAPE.

ABBVIE'S RINVOQ GAINS EARLY TRACTION IN GIANT CELL ARTERITIS MARKET, EXPANDING OPTIONS FOR RHEUMATOLOGISTS

NEW AA (ALLERGAN AESTHETICS) SIGNATURE MULTIMODAL TREATMENT APPROACH TO BE PRESENTED AT AMWC DUBAI FOLLOWING SUCCESSFUL LAUNCH IN 25 COUNTRIES SO FAR THIS YEAR. EXPERTS TO EXPLORE THE PARADIGM SHIFT IN MEDICAL AESTHETICS AND DECODE NEW AA SIGNATURE APPROACH AT ALLERGAN MEDICAL INSTITUTE (AMI) SYMPOSIUM.

ALLERGAN AESTHETICS TO SHOWCASE MULTIMODAL TREATMENT APPROACH AND CONTINUED COMMITMENT TO SKIN QUALITY AT AMWC DUBAI

SKINVIVE  TO LAUNCH IN 35 ADDITIONAL MARKETS WORLDWIDE FROM SEPTEMBER TAKING THE TOTAL TO 57 INTERNATIONAL LAUNCHES IN 2025. RESEARCH HIGHLIGHTS 94% OF PEOPLE WANT TO IMPROVE FACIAL SKIN QUALITY1*, WITH DEEP HYDRATION VALUED ACROSS ALL AGES WORLDWIDE2.

AbbVie Inc.

ABBV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ABBV